It is intended as an adjunct in abdominal and pelvic surgery for reducing the incidence, extent and severity of postoperative adhesions at the site of placement.
It should be applied to sites of potentially adhesiogenic tissue and organ structures in the abdominopelvic cavity to serve as a temporary barrier separating opposing tissue surfaces.
It is contraindicated in patients with a history of hypersensitivity to itand/or to any component of Seprafilm.
Gastrointestinal Disorders: intra-abdominal fluid collection General disorders and administration site conditions: foreign body (fibrotic) reaction, inflammation Immune System Disorders: hypersensitivity Infections and infestations: sepsis, peritonitis, abscess, post-procedural wound infection/wound dehiscence Injury, poisoning and procedural complications: anastomotic leak Muscoloskeletal and connective tissue disorders: fistula
No clinical studies have been conducted in pregnant women or women who become pregnant in the first month after application of Seprafilm. Therefore, this product is not recommended for use during pregnancy and avoiding of pregnancy during the first complete menstrual cycle after the use of itshould be considered.
.png&w=384&q=75)